In vivo Efficacy Studies of ATx201 Compares Favorably with Marketed Products

COPENHAGEN, AUGUST 07, 2016 – Recent in vivo studies in mice documents the antibacterial properties of ATx201 and that they compare favorably to marketed products. The CSO of AntibioTx, Dr. Morten Sommer, said “ATx201 looks promising in numerous points such as treatment duration, de novo resistance and effectiveness against multi-drug resistant bacteria including MRSA. We strongly believe that ATx201 will be a valuable asset in treating microbiome related disorders”. This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements. 13 Responses Pingback: get androxal canada no prescription Pingback: get enclomiphene cheap canadian pharmacy Pingback: discount rifaximin uk buy over counter Pingback: purchase xifaxan generic information Pingback: ordering staxyn australia no prescription Pingback: does generic avodart from canada work Pingback: order dutasteride generic brand Pingback: order flexeril cyclobenzaprine buy in the uk Pingback: cheap gabapentin purchase uk Pingback: order fildena australia generic online Pingback: get itraconazole australia discount Pingback: nejlevnější kamagra online bez lékařského předpisu Pingback: kamagra à vendre canada Comments are closed.

The release as fetched from its publisher. uniontherapeutics.com ↗